年龄对利福喷丁周疗方案治疗潜伏性结核感染结局的影响
总体完成率为83.1%,年轻组最高(94.5%),老年组最低(73.9%)。中年组全身性药物反应风险为17.1%,是老年组的3.04倍(P = .025)。
要点
- 在规范医疗支持和项目随访下,老年参与者3HP完成率仍可达70%以上。
- 中年人群使用3HP需警惕全身性药物反应风险。
- 老年人群使用3HP需警惕高血压事件伴随流感样症状。
核心结论
- 在适当医疗支持和项目随访下,3HP完成率在老年参与者中仍超过70%。
- 中年和老年个体使用3HP应分别谨慎对待全身性药物反应和高血压事件风险。
研究设计与样本
- 参与者按年龄分为老年组(≥65岁)、中年组(>35且<65岁)和年轻组(≤35岁)。
主要发现
- 总体完成率为83.1%,年轻组最高(94.5%),老年组最低(73.9%)。
- 多因素logistic回归分析显示3组间3HP停药率无显著差异。
- 362例(62.5%)参与者发生至少1种药物不良反应,其中38例(10.5%)需暂时中断治疗,98例(27.1%)需永久中断治疗。
- 总体全身性药物反应风险为11.2%,中年组为17.1%,是老年组的3.04倍(P = .025)。
- 老年参与者中11.2%发生伴随流感样症状的高血压事件,占≥3级不良反应的50%。
临床怎么用
- 在规范医疗支持和项目随访下,可对老年人群使用3HP方案,但需监测完成情况。
- 对中年人群使用3HP时应警惕全身性药物反应。
- 对老年人群使用3HP时应警惕高血压事件伴随流感样症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Weekly rifapentine and isoniazid (3HP) is gaining popularity for latent tuberculosis infection treatment because of its short course and high completion rate. Prior to widespread use, comprehensive 3HP treatment assessment covering an all-age population is essential. METHODS: Participants receiving ≥1 3HP dose from September 2014 to December 2019 were stratified into elderly (≥65 years), middle-aged (>35 & <65 years), and younger (≤35 years) age groups. This study investigated the impact of age on treatment outcome, particularly systemic drug reactions (SDRs) and 3HP discontinuation. RESULTS: Overall, 134 of 579 (23.1%) participants were elderly. The completion rate was 83.1% overall and was highest and lowest in the younger group (94.5%) and elderly (73.9%) group, respectively. However, the 3HP discontinuation rate was not significantly different among the 3 groups in multivariate logistic regression analysis. In total, 362 (62.5%) participants experienced 1 or more adverse drug reactions (ADRs), of which 38 (10.5%) and 98 (27.1%) required temporary and permanent treatment interruption, respectively. The SDR risk was 11.2% in overall and 17.1% in the middle-aged group, 3.04-fold higher than that in the elderly group (P = .025). This finding was consistently observed in different clinical settings. Hypertensive events accompanied with flu-like symptoms occurred in 11.2% of elderly participants, and accounted for 50% of grade ≥3 ADRs. CONCLUSIONS: With proper medical support and programmatic follow-up, the 3HP completion rate is >70% even in elderly participants. In middle-aged and elderly individuals, 3HP should be employed with caution because of risk of SDRs and hypertensive events, respectively. Summary: Under programmatic medical support, widespread use of weekly rifapentine and isoniazid (3HP) for latent tuberculosis treatment is possible for its high completion rate. 3HP should be employed with caution for risk of systemic drug reactions and hypertensive events in middle-aged and elderly individuals, respectively.
引用
- Huang HL, Lee MR, Cheng MH, et al. Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection. Clin Infect Dis. 2021. PMID: 33215187. doi:10.1093/cid/ciaa1741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。